Cosmos Health Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $12.8M
- Price
- $0.1949
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.98%
- Volume
- 4.7M
About
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.
Quick stats
Shares outstanding62.1M
Computed float40.1M
Float / shares64.6%
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001474167
AI Summary
AI-generated1/50
majorbullishearnings
Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway
Cosmos Health reported record second-quarter revenue of $18.99 million, up 29% year-over-year, and a record first half of $36.91 million, driven by growth across all core divisions including Decahedron, Cana Laboratories, and CosmoFarm.
Operational metrics improved significantly, with adjusted gross profit rising 58% to $1.84 million and adjusted gross margin expanding 165 basis points to 9.54%, while operating expenses grew at roughly half the rate of revenue.
The company strengthened its balance sheet by reducing total liabilities by $6.27 million and increasing stockholders' equity by 12% to $20.67 million, while actively executing a $5 million share repurchase program.